Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acurx Pharmaceuticals Inc (NQ: ACXP )

2.150 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acurx Pharmaceuticals Inc

< Previous 1 2 Next >
New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET
Via ACCESSWIRE
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
Via AB Newswire
Acurx Pharmaceuticals’ Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
Exposures Death
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
In The Queue: AcurX Pharmaceuticals Earnings…Here’s What Investors Need To Know Before Thursday ($ACXP)
Via AB Newswire
Exposures Product Safety
Race To The Cure: Here’s Why Acurx Pharmaceuticals Could Win The Battle To Treat C. difficile ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals CEO Is Confident His Ibezapolstat Can Earn Front-Line Designation To Treat C. difficile…Here’s Why ($ACXP)
Via AB Newswire
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diff
C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United... 
Via TheNewswire.com
Topics Death
Exposures Death Product Safety
Acurx Pharmaceuticals Surges 29% In August, Here’s Why The ACXP Bulls Expect Much More To Come ($ACXP)
Via AB Newswire
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals’ Phase 2b Antibiotic Candidate To Treat C. Difficile Shows 100% Cure And 100% Sustained Cure In Potentially Transformative Study (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)
Via AB Newswire
If A Santa Claus Rally Comes To Town, Expect Acurx Pharmaceuticals To Be On The Lead Sleigh…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
With A Phase 2b Trial In Progress, Acurx Pharmaceuticals May be The Most Undervalued Biotech On The Market…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Stock Spikes 10% After Reaching Phase 2b Milestone Evaluating Ibezapolstat To Treat CDI (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals’ Drug Candidate Ibezapolstat Continues To Score Clinical Wins In Treating C. Difficile (NASDAQ: ACXP)
Via AB Newswire
AcurX Pharmaceuticals’ C. Difficile Drug Candidate Could Fetch $800 Million On A Peer Comparison Basis (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
VIDEO Report: Acurx Pharmaceuticals’ Ibezapolstat In Focus As A Best-In-Class Treatment For Gram Positive Infections (NASDAQ: ACXP)
Via AB Newswire
CEO In Focus: Acurx Pharma CEO Confident His Company’s Phase 2b Ibezapolstat Trial Can Lead To A Front-Line Treatment For C. difficile (NASDAQ: ACXP)
Via AB Newswire
CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts
New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing... 
Via Newsfile
Topics Death Derivatives Initial Public Offering
Exposures Death Derivatives Intellectual Property
Acurx Pharmaceutical’s Reaches Another Milestone With Russell Microcap Inclusion; Shares Extend August Gains (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceutical’s Is Disruptive To The Antibiotics Landscape- That’s Great News For Patients With Gram-Positive Infections (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better Drugs That Target Gram-Positive Infections
Via AB Newswire
Acurx Pharmaceutical’s On Pace To Change The Antibiotics Landscape; Trial Data Shows 100% Sustained Clinical Cure In Treating Gram-Positive Infection CDI
Via AB Newswire
Drug Makers Overseas Are Gaining A Competitive Advantage In The Antibiotics R&D Market; Acurx Pharmaceuticals Ibezapolstat Program Is Helping Level The Field (NASDAQ: ACXP)
Via AB Newswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.